ArticleBritish journal of haematology2022
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Article in British journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.ESMO open · 2022Guideline
- Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.Advances in therapy · 2025Review
- Impact of the COVID-19 pandemic on care delivery, follow-up and outcomes in chronic myeloid leukemia patients: An observational cohort study.Bioinformation · 2024Article
- COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.Frontiers in immunology · 2024Article
- Article
- Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.Annals of hematology · 2023Article
- SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.Journal of cancer research and clinical oncology · 2023Article
- Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.Medicina (Kaunas, Lithuania) · 2023Article
- The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.Leukemia · 2023Article
- Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization.Cancer medicine · 2023Article
- Management of chronic myelogenous leukemia with COVID-19 and hepatitis B.Frontiers in oncology · 2023Review
- Article
- COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report.Haematologica · 2022Article
- Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19.Journal of clinical medicine · 2022Article
- Management of Newly Diagnosed Chronic Myeloid Leukemia During COVID-19 Hospitalization: A Teaching Case.Cureus · 2022Article
- Is COVID-19 less severe in CML patients than in those with other haematological cancers?British journal of haematology · 2022Article
- COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study.Ecancermedicalscience · 2022Article
- Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.Frontiers in oncology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
49 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most patients (57%) were diagnosed as having SARS-CoV-2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty-six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS-CoV-2 infection was six years (three months to 18 years). Twenty-one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty-three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID-19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS-CoV-2 infection and an impact of the pandemic on the overall management of CML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.